Latest Pharma and Biotech News
Pharmaceutical
20 March 2025 Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate).
Today's issue
Refine Search
Biotechnology
US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a reduction in research staff and key leadership changes. 21 March 2025
Pharmaceutical
Japanese ophthalmology company Santen Pharmaceutical announced that it will launch Ryjusea Mini solution 0.025% (tropine sulfate hydrate) on April 21, 2025. 21 March 2025
Biotechnology
US pharma major Johnson & Johnson has won US approval for Tremfya (guselkumab) in the treatment of adults with moderately to severely active Crohn’s disease, further expanding the immunology drug’s footprint and reinforcing the company’s efforts to replace revenue from declining Stelara (ustekinumab) sales. 21 March 2025
Biotechnology
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Biotechnology
Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was being developed for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. 20 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules. 20 March 2025
Biotechnology
Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior standard therapies. 20 March 2025
Pharmaceutical
Pharmaceutical leaders are warning that the UK is becoming an unattractive destination for investment due to high and unpredictable levies on medicine sales. 20 March 2025
Biotechnology
Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene therapies (CGT). 20 March 2025
Biotechnology
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy (DMD). 20 March 2025
Biotechnology
French pharma major Sanofi today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. 20 March 2025
Pharmaceutical
The Indian subsidiary of US pharma major Eli Lilly (NYSE: LLY) has announced the launch of Mounjaro (tirzepatide) in single-dose vial presentation. This follows the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). 20 March 2025
Biotechnology
Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 negative, unresectable or recurrent breast cancer after prior chemotherapy. 20 March 2025
Pharmaceutical
Purdue Pharma has filed a Chapter 11 Plan of Reorganization and related disclosure statement with the US Bankruptcy Court for the Southern District of New York. 20 March 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s Keytruda (pembrolizumab) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1). 20 March 2025
Biotechnology
Swiss pharma major Novartis has announced positive results from its Phase III STEER study, evaluating the efficacy and safety of intrathecal onasemnogene abeparvovec (OAV101 IT) in patients aged 2 to under 18 with spinal muscular atrophy (SMA) Type 2. 19 March 2025
Pharmaceutical
Whitehawk Therapeutics , formerly Aadi Bioscience, has officially rebranded to reflect its transformation into a pre-clinical-stage biotech focused on antibody-drug conjugates (ADCs). 19 March 2025
Pharmaceutical
Swiss pharma major Novartis is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a restructuring effort ahead of expected generic competition for its top-selling heart failure drug, Entresto (sacubitril/valsartan). 19 March 2025
All news
Biotechnology
US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a reduction in research staff and key leadership changes. 21 March 2025
Pharmaceutical
Japanese ophthalmology company Santen Pharmaceutical announced that it will launch Ryjusea Mini solution 0.025% (tropine sulfate hydrate) on April 21, 2025. 21 March 2025
Biotechnology
US pharma major Johnson & Johnson has won US approval for Tremfya (guselkumab) in the treatment of adults with moderately to severely active Crohn’s disease, further expanding the immunology drug’s footprint and reinforcing the company’s efforts to replace revenue from declining Stelara (ustekinumab) sales. 21 March 2025
Biotechnology
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Biotechnology
Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was being developed for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. 20 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences today presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules. 20 March 2025
Biotechnology
Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior standard therapies. 20 March 2025
Pharmaceutical
Pharmaceutical leaders are warning that the UK is becoming an unattractive destination for investment due to high and unpredictable levies on medicine sales. 20 March 2025
Biotechnology
Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene therapies (CGT). 20 March 2025
Biotechnology
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy (DMD). 20 March 2025
Biotechnology
French pharma major Sanofi today revealed it has entered into a definitive agreement with privately-held US biotech Dren Bio, to acquire the latter’s DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. 20 March 2025
Pharmaceutical
The Indian subsidiary of US pharma major Eli Lilly (NYSE: LLY) has announced the launch of Mounjaro (tirzepatide) in single-dose vial presentation. This follows the marketing authorization from the Central Drugs Standard Control Organization (CDSCO). 20 March 2025
Biotechnology
Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 negative, unresectable or recurrent breast cancer after prior chemotherapy. 20 March 2025
Pharmaceutical
Purdue Pharma has filed a Chapter 11 Plan of Reorganization and related disclosure statement with the US Bankruptcy Court for the Southern District of New York. 20 March 2025
Biotechnology
The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s Keytruda (pembrolizumab) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1). 20 March 2025
Biotechnology
Swiss pharma major Novartis has announced positive results from its Phase III STEER study, evaluating the efficacy and safety of intrathecal onasemnogene abeparvovec (OAV101 IT) in patients aged 2 to under 18 with spinal muscular atrophy (SMA) Type 2. 19 March 2025
Pharmaceutical
Whitehawk Therapeutics , formerly Aadi Bioscience, has officially rebranded to reflect its transformation into a pre-clinical-stage biotech focused on antibody-drug conjugates (ADCs). 19 March 2025
Pharmaceutical
Swiss pharma major Novartis is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a restructuring effort ahead of expected generic competition for its top-selling heart failure drug, Entresto (sacubitril/valsartan). 19 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze